Stay updated with breaking news from Recognify Life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial
Over 90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly. Out of emerging therapies, AVP-786 is in Phase II/III stage of trials. Similarly, MK-8189 is undergoing Phase II developmental phase for Schizophrenia. Schizophrenia pipeline therapies in the early stages of development include CAD-9303, and In December 2020, FDA assigns PDUFA action date of (01/06/2021) for ALKS 3831 for Schizophrenia and Bipolar disorders. In June 2020, Neurocrine Biosciences and ...